BAYER AKTIENGESELLSCHAFT 4
4 · Metagenomi, Inc. · Filed Feb 15, 2024
Insider Transaction Report
Form 4
BAYER HEALTHCARE LLC
10% Owner
Transactions
- Conversion
Common Stock
2024-02-13+1,770,888→ 1,770,888 total - Conversion
Common Stock
2024-02-13+1,180,592→ 2,951,480 total - Conversion
Common Stock
2024-02-13+589,662→ 3,541,142 total - Conversion
Common Stock
2024-02-13+509,855→ 4,050,997 total - Conversion
Series A-1 Convertible Preferred Stock
2024-02-13−3,093,580→ 0 total→ Common Stock (1,770,888 underlying) - Conversion
Series A-4 Convertible Preferred Stock
2024-02-13−2,062,387→ 0 total→ Common Stock (1,180,592 underlying) - Conversion
Series B Convertible Preferred Stock
2024-02-13−1,030,086→ 0 total→ Common Stock (589,662 underlying) - Conversion
Series B-1 Convertible Preferred Stock
2024-02-13−890,671→ 0 total→ Common Stock (509,855 underlying)
Footnotes (5)
- [F1]Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO").
- [F2]The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
- [F3]Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.
- [F4]Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.
- [F5]Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.